Five Key Factors Weighing on Dendreon

Shares of Dendreon Corporation (DNDN) have declined significantly from an all-time high of $57.67 in late April 2010 when the company received U.S. Food and Drug Administration [FDA] approval for Provenge® [sipuleucel-T], the first active immunotherapy approved for the treatment of cancer in the U.S.  Today, shares of Dendreon traded as low as $28.01, down … Read moreFive Key Factors Weighing on Dendreon

Much Ado About Medarex

According to their website, Discovery’s Edge is the Mayo Clinic’s online research magazine that is designed to communicate the story of scientists and researchers who are bringing treatments and improved care to patients and also reports on “works–in–progress.”  Through this publication, Mayo investigators studying immunotherapy for aggressive prostate cancer reported over the past weekend that … Read moreMuch Ado About Medarex

Molecular Insight Pharmaceuticals: In the Prostate Cancer Spotlight

Prostate cancer is the most common type of cancer found in American men, other than skin cancer. In 2009, the American Cancer Society estimates that there will be nearly 200,000 new cases of prostate cancer in the United States and that about 27,000 men will die from the disease. It is estimated that there are … Read moreMolecular Insight Pharmaceuticals: In the Prostate Cancer Spotlight

Biotech Stocks and the ASCO-effect

Investors are hoping that the spark that could reignite investor enthusiasm for biotech stocks is taking place right now. Approximately 30,000 participants are gathering from May 29-June 2, 2009, in Orlando, Florida, for the year’s largest cancer conference. Attendees of the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) will exchange ideas … Read moreBiotech Stocks and the ASCO-effect